| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL1RL1 |
| Uniprot No | Q13445 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-227aa |
| 氨基酸序列 | MMAAGAALALALWLLMPPVEVGGAGPPPIQDGEFTFLLPAGRKQCFYQSAPANASLETEYQVIGGAGLDVDFTLESPQGVLLVSESRKADGVHTVEPTEAGDYKLCFDNSFSTISEKLVFFELIFDSLQDDEEVEGWAEAVEPEEMLDVKMEDIKESIETMRTRLERSIQMLTLLRAFEARDRNLQEGNLERVNFWSAVNVAVLLLVAVLQVCTLKRFFQDKRPVPT |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL1RL1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by TLR ligands"*
**作者**: Savinko T, et al.
**摘要**: 研究通过重组IL1RL1(ST2)蛋白探究其与IL-33的相互作用在特应性皮炎中的作用，发现TLR配体可上调皮肤细胞中ST2表达，促进Th2炎症反应。
---
2. **文献名称**: *"Recombinant soluble ST2 protein inhibits tumor growth and metastasis in a murine melanoma model"*
**作者**: Kim SH, et al.
**摘要**: 利用重组sST2蛋白阻断IL-33/ST2信号通路，发现其通过抑制血管生成和调节免疫微环境显著抑制黑色素瘤生长和转移。
---
3. **文献名称**: *"Structural basis of IL-33 recognition by its receptor ST2LR and co-receptor IL-1RAcP"*
**作者**: Liu X, et al.
**摘要**: 通过X射线晶体学解析重组IL1RL1胞外域与IL-33及共受体IL-1RAcP的三元复合物结构，揭示ST2特异性识别IL-33的分子机制。
---
**备注**：IL1RL1(ST2)相关研究多集中于其在炎症、纤维化及肿瘤中的作用，重组蛋白常被用于信号机制探索或潜在治疗策略开发。
IL1RL1 (Interleukin 1 Receptor-Like 1), also known as ST2 (Suppression of Tumorigenicity 2), is a member of the interleukin-1 receptor (IL-1R) family. It exists in two primary isoforms: a membrane-bound form (ST2L) that functions as a receptor and a soluble form (sST2) that acts as a decoy receptor. IL1RL1 gained prominence due to its role as the receptor for interleukin-33 (IL-33), a cytokine involved in immune and inflammatory responses. The IL-33/ST2 signaling axis is critical in Th2-mediated immune pathways, influencing conditions such as asthma, allergic inflammation, and fibrosis. Additionally, sST2 has emerged as a biomarker in cardiovascular diseases, particularly heart failure, where elevated levels correlate with adverse outcomes.
Recombinant IL1RL1 protein is typically produced using expression systems (e.g., mammalian, insect, or bacterial cells) to generate purified forms of the extracellular domain, enabling functional and structural studies. This protein is instrumental in dissecting IL-33/ST2 interactions, screening therapeutic agents, or developing diagnostic assays. In research, recombinant IL1RL1 helps elucidate mechanisms underlying inflammatory diseases and fibrotic processes, while clinically, it aids in standardizing sST2 measurements for prognostic evaluation. Its applications extend to therapeutics, including blocking IL-33 signaling in autoimmune disorders or leveraging its decoy function to modulate excessive inflammation. Challenges in production include maintaining proper post-translational modifications for bioactivity, often addressed via mammalian cell systems. Overall, IL1RL1 recombinant protein serves as a vital tool bridging basic research and translational medicine.
×
